Publications by authors named "S Hojo"
Article Synopsis
- The study investigates the heart's energy dynamics during acute heart failure (HF) to understand what happens during decompensation, which is when the heart can't pump effectively.
- It involved 50 patients with decompensated HF, measuring intracardiac energy loss (EL) using echo-vector flow mapping at both admission and discharge, comparing results with 40 stable patients who do not have HF.
- Findings showed that energy loss in the left ventricle increased significantly in decompensated HF cases compared to compensated ones, indicating energy inefficiency in the heart, especially among patients with preserved ejection fraction.
Article Synopsis
- This study is a follow-up on the effectiveness and safety of tazemetostat for Japanese patients with relapsed/refractory follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) who have the EZH2 mutation, after a median follow-up of 35 months.
- The FL cohort had an impressive objective response rate of 70.6%, with significant progression-free survival (PFS) rates at 24 and 36 months (72.1% and 64.1% respectively), while no unexpected severe adverse events were reported.
- Overall, long-term treatment with tazemetostat appears to be a promising and safe option as a third-line or later therapy for patients with this specific
Article Synopsis
- Atrial fibrillation (AF) ablation often leads to early arrhythmia recurrences due to inflammation, prompting the study of Saireito as a potential treatment to reduce these occurrences.
- A randomized trial with 100 patients compared the effects of a 30-day Saireito treatment against a control group, focusing on the frequency of atrial tachyarrhythmias post-ablation.
- Results showed that while the Saireito group had fewer episodes of arrhythmias in the first two weeks, they also experienced more adverse symptoms compared to the control group.
Aim: To compare the outcomes of therapy using recombinant human fibroblast growth factor (rhFGF)-2 combined with autologous bone grafting (ABG) therapy with those of rhFGF-2 alone and ABG alone in the treatment of periodontal intraosseous defects.
Methods: Periodontal intraosseous defects were randomized to receive rhFGF-2 therapy + ABG, rhFGF-2 therapy alone, or ABG alone. Periodontal examination and periapical radiography were performed preoperatively and at 3, 6, and 12 months postoperatively.